1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Alamar Biosciences enters strategic collaboration with SciLifeLab to advance translational proteomics and accelerate biomarker discoveryenters strategic collaboration with SciLifeLab to advance translational proteomics and accelerate biomarker discovery

30 May 2025
Admin
News Article

Alamar Biosciences enters strategic collaboration with SciLifeLab to advance translational proteomics and accelerate biomarker discovery

Alamar Biosciences, a company leading innovation in precision proteomics, has announced a strategic collaboration with SciLifeLab, Sweden’s national center for molecular biosciences. The goal is to accelerate translational proteomics and advance biomarker discovery for the earliest detection of disease.

Combining Cutting-Edge Technologies and Resources

This partnership integrates:

Alamar’s NULISA technology and ARGO HT system, which provide ultra-sensitive, multiplexed protein analysis from biofluids.
SciLifeLab’s proteomics expertise and extensive research infrastructure, including the Human Protein Atlas, a renowned project mapping the human proteome.

Together, these resources aim to deepen the understanding of disease biology and support the development of early diagnostic tools.

Leadership Comments on the Collaboration

“We are thrilled to partner with SciLifeLab in this important work. Our combined technologies will provide comprehensive data on protein expression and localization, which will be instrumental in validating signatures discovered using the NULISA platform.”

said Dr. Yuling Luo, Chairman, Founder & CEO of Alamar Biosciences.

“SciLifeLab’s expertise in affinity proteomics, combined with our national infrastructure and partnership with National Genomics Infrastructure, makes this a natural environment for a cutting-edge technology like the ARGO HT System. We look forward to enabling new levels of sensitivity, scalability, and integration in biomarker discovery.”

said Professor Jochen Schwenk, SciLifeLab Group Leader and Platform Scientific Director of Proteomics.

About Alamar Biosciences

Alamar Biosciences is a privately held life sciences company focused on powering precision proteomics to enable the earliest detection of disease.

Its proprietary NULISA platform and ARGO HT System work seamlessly with advanced genomics.
These technologies achieve single-digit attomolar sensitivity, surpassing the detection limits of existing protein analysis platforms.

About SciLifeLab

SciLifeLab is Sweden’s national center for molecular biosciences, jointly operated by:

Karolinska Institutet
KTH Royal Institute of Technology
Stockholm University
Uppsala University

The center offers:

Unique research infrastructure
Comprehensive data resources
Collaborative opportunities across academia, healthcare, and industry

It plays a key role in enabling scientific breakthroughs through national and international collaborations.